Age (y), median (IQR) | 81.0 (75.0–86.0) | 80.0 (74.0–87.0) | 80.0 (75.0–86.0) |
Female, n (%) | 98 (62) | 73 (51) | 171 (57) |
BMI (kg/m2), median (IQR) | 27.9 (24.6–31.6) | 26.8 (23.9–30.3) | 27.3 (23.9–31.2) |
Aspirin or P2Y12 receptor blocker, n (%) | 54 (34) | 27 (19) | 81 (27) |
Statin, n (%) | 97 (62) | 101 (70) | 197 (66) |
Tobacco usage, n (%) | | | |
Never | 124 (80) | 113 (79) | 237 (79) |
Current | 8 (5) | 9 (6) | 17 (6) |
Past | 23 (15) | 21 (15) | 44 (15) |
Total cholesterol (mg/dL), median (IQR) | 154 (129–179) | 148 (121–173) | 149 (124–177) |
LDL (mg/dL), median (IQR) | 79 (60–99) | 77 (61–99) | 77 (60–91) |
Cockcroft-Gault CrCl (mL/min/1.73 m2), median (IQR) | 50.2 (35.7–70.1) | 58.1 (43.3–70.0) | 54.2 (38.2–70.0) |
MDRD CrCl (mL/min/1.73 m2), median (IQR) | 63.1 (42.7–78.2) | 66.3 (51.8–82.6) | 64.3 (46.7–80.6) |
History of hypertension, n (%) | 135 (86) | 126 (88) | 261 (87) |
Any history of thromboembolism, n (%) | 90 (57) | 89 (62) | 179 (59) |
History of stroke, n (%) | 39 (25) | 37 (26) | 76 (25) |
History of TIA, n (%) | 7 (4) | 20 (14) | 27 (9) |
Evidence of vascular damage on imaging, n (%) | 19 (12) | 18 (13) | 37 (12) |
History of MI, n (%) | 44 (28) | 36 (25) | 80 (27) |
History of systemic thromboembolism, n (%) | 7 (4) | 6 (4) | 13 (4) |
Recent thromboembolic event (3 mo), n (%) | | | |
Stroke | 4 (3) | 3 (2) | 7 (2) |
MI | 4 (3) | 4 (3) | 8 (3) |
CHF, n (%) | 76 (48) | 62 (43) | 138 (46) |
PVD, n (%) | 26 (17) | 20 (14) | 46 (15) |
DM, n (%) | 61 (39) | 58 (40) | 119 (40) |
Charlson score, median (IQR) | 6.0 (5.0–7.0) | 6.0 (5.0–8.0) | 6.0 (5.0–7.0) |
CHA2DS2-VASc score, median (IQR) | 5.0 (4.0–6.0) | 5.0 (4.0–6.0) | 5.0 (4.0–6.0) |
CHADS2, median (IQR) | 4.0 (3.0–5.0) | 4.0 (3.0–5.0) | 4.0 (3.0–5.0) |
Subtherapeutic enoxaparin, n (%) | 51 (32) | 48 (33) | 99 (33) |
Interruption length (d), median (IQR) | 10.0 (5–20) | 5.0 (4.0–8.0) | 7.0 (4.0–7.0) |